TABLE 1

Patient characteristics for sputum SomaLogic analyses

CSAMissing valuesESAMissing valuesNSAMissing valuesHealthy
nonsmokers
Missing valuesp-value
Subjects11223718
Female5 (45.5)14 (63.6)22 (59.5)6 (33.3)2.01×10−1
Age years50.0±10.655.7±9.752.6±13.339.9±13.8##,¶¶3.95×10−3+
Onset age of asthma years29.8±19.939.5±19.0¶¶25.0±18.12.45×10−2+
Age at starting smoking years19.3±4.016.2±2.54.93×10−2§
Years of smoking cessation13.7±10.5
Smoking pack-years29.0±18.220.8±16.10±00±01.17×10−1§
BMI kg·m−227.7±4.731.1±6.727.5±5.725.3±3.2##2.79×10−2+
Atopic8 (88.9)210 (62.5)628 (84.8)45 (45.5)73.60×10−2
Blood eosinophils cells·μL−1259±173296±246407±3572116±713.31×10−1+,ƒ
Blood neutrophils ×103 cells·μL−15.10±1.955.84±3.034.97±2.1623.35±1.156.03×10−1+,ƒ
Sputum eosinophils %7.2±15.214.8±16.818.8±24.60.36±0.572.98×10−1+,ƒ
Sputum neutrophils %53.9±16.155.2±20.650.8±30.941.0±26.59.28×10−1+,ƒ
IgE IU·mL−1222±2012313±499305±5103105±1788.84×10−1+,ƒ
FeNO ppb15.2±16.6##,¶¶40.5±33.9141.2±36.3319.4±9.73 7.55×10−4+,ƒ
Periostin ng·mL−142.8±9.3253.1±18.9454.9±20.3949.7±5.542.66×10−1+,ƒ
FEV1 post-bronchodilator# %73.7±18.278.8±21.168.6±21.1105.2±11.51.82×10−1+,ƒ
FEV1/FVC post-bronchodilator# %61.5±10.163.4±12.260.2±13.979.0±5.96.27×10−1+,ƒ
Airway reversibility %15.0±9.516.7±12.717.3±20.417.45×10−1+
Airflow limitation (missing data n=92 overall)7 (63.6)11 (50.0)28 (75.7)1.33×10−1
Average ACQ-72.87±1.3112.67±0.9832.68±1.1948.30×10−1+
Average AQLQ4.15±1.5714.62±1.0454.35±1.2925.06×10−1+
Exacerbations in previous year2.6±3.32.1±1.92.4±1.97.47×10−1+
ER visits due to breathing problems5 (45.5)14 (63.6)25 (62.2)4.41×10−1
Comorbidities
 Allergic rhinitis2 (25.0)38 (40.0)216 (55.2)82.85×10−1
 Nasal polyps2 (20.0)17 (33.3)112 (34.3)27.20×10−1
 Sinusitis2 (25.0)36 (28.6)19 (28.1)51.00
 Chronic bronchitis1 (11.1)12 (9.1)4 (12.1)41.00
 Psychiatric disease3 (33.3)23 (14.3)15 (13.9)13.84×10−1
 GORD4 (50.0)315 (71.4)¶¶111 (32.4)31.74×10−2
Medications
 Inhaled corticosteroids11 (100.0)22 (100.0)37 (100.0)1.00
 Systemic corticosteroids3 (30.0)114 (63.6)16 (45.7)21.93×10−1
 Oral corticosteroid dose mg·day−12.50±4.7117.89±8.0134.18±6.6128.53×10−2+
 Anti-IgE therapy0 (0.0)12 (4.0)20 (0.0)21.13×10−1
 Long-acting β-agonists11 (100.0)21 (95.5)37 (100.0)4.71×10−1
 Leukotriene modifiers4 (36.4)11 (52.4)119 (51.4)6.80×10−1
 Tiotropium3 (30.0)14 (22.2)212 (34.3)25.61×10−1
 Macrolide2 (18.2)3 (13.6)4 (10.8)7.96×10−1

Data are presented as n, n (%) or mean±sd, unless otherwise stated. Bold type represents statistical significance (p<0.05). CSA: severe asthma current smokers; ESA: severe asthma ex-smokers; NSA: severe asthma nonsmokers; BMI: body mass index; Ig: immunoglobulin; FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: asthma control questionnaire; AQLQ: asthma quality of life questionnaire; ER: emergency room; GORD: gastro-oesophageal reflux disease. #: spirometry data without bronchodilator were used for healthy subjects; statistical analysis was performed using : Fisher's exact test, +: Kruskal–Wallis test; or §: Mann–Whitney U-test; ƒ: healthy subjects were excluded from statistical analyses of several items; ##: p<0.05 versus ESA; ¶¶: p<0.052 versus NSA.